Search Page

1

Cite

Share

Maintaining plasma quality and safety in the state of ongoing epidemic - The role of pathogen reduction.

Wasiluk T, Rogowska A, Boczkowska-Radziwon B, Zebrowska A, Bolkun L, Piszcz J, Radziwon P. Wasiluk T, et al. Among authors: bolkun l. Transfus Apher Sci. 2020 Sep 28:102953. doi: 10.1016/j.transci.2020.102953. Online ahead of print. Transfus Apher Sci. 2020. PMID: 33023853 Free PMC article. Review.

Cite

Share

2

Cite

Share

Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group.

Markiewicz M, Drozd-Sokolowska J, Biecek P, Dzierzak-Mietla M, Boguradzki P, Staniak M, Piatkowska-Jakubas B, Piekarska A, Tormanowska M, Halaburda K, Ussowicz M, Waszczuk-Gajda A, Basak G, Bołkun L, Rybka J, Sadus-Wojciechowska M, Giebel S, Szmigielska-Kaplon A, Mendek-Czajkowska E, Warzybok K, Burdacki A, Dwilewicz-Trojaczek J. Markiewicz M, et al. Among authors: bolkun l. Biol Blood Marrow Transplant. 2020 Oct;26(10):1833-1839. doi: 10.1016/j.bbmt.2020.05.024. Epub 2020 Jun 6. Biol Blood Marrow Transplant. 2020. PMID: 32512214 Free article.

Cite

Share

3

Cite

Share

Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival.

Sellers ZP, Bolkun L, Kloczko J, Wojtaszewska ML, Lewandowski K, Moniuszko M, Ratajczak MZ, Schneider G. Sellers ZP, et al. Among authors: bolkun l. Clin Epigenetics. 2019 Mar 15;11(1):50. doi: 10.1186/s13148-019-0643-z. Clin Epigenetics. 2019. PMID: 30876483 Free PMC article.

Cite

Share

4

Cite

Share

High immunoproteasome concentration in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of longer OS.

Breczko W, Lemancewicz D, Dzięcioł J, Kłoczko J, Bołkun Ł. Breczko W, et al. Among authors: bolkun l. Adv Med Sci. 2020 Nov 24;66(1):21-27. doi: 10.1016/j.advms.2020.11.003. Online ahead of print. Adv Med Sci. 2020. PMID: 33246214

Cite

Share

5

Cite

Share

Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).

Pluta A, Robak T, Brzozowski K, Stepka K, Wawrzyniak E, Krawczynska A, Czemerska M, Szmigielska-Kaplon A, Grzybowska-Izydorczyk O, Nowicki M, Stelmach P, Kuydowicz M, Gromek T, Hus M, Helbig G, Grosicki S, Bodzenta E, Razny M, Wojcik K, Bolkun L, Kloczko J, Knopinska-Posluszny W, Piekarska A, Hellman A, Sobas M, Wrobel T, Patkowska E, Lech-Maranda E, Warzocha K, Holowiecki J, Giebel S, Wierzbowska A. Pluta A, et al. Among authors: bolkun l. Leuk Lymphoma. 2020 Mar;61(3):588-603. doi: 10.1080/10428194.2019.1678151. Epub 2019 Oct 29. Leuk Lymphoma. 2020. PMID: 31661339

Cite

Share

6

Cite

Share

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia. Buske C, et al. Among authors: bolkun l. Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Lancet Haematol. 2018. PMID: 29958569 Review.

Cite

Share

7

Cite

Share

Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.

Mądry K, Lis K, Biecek P, Młynarczyk M, Rytel J, Górka M, Kacprzyk P, Dutka M, Rodzaj M, Bołkun Ł, Krochmalczyk D, Łątka E, Drozd-Sokołowska J, Waszczuk-Gajda A, Knopińska-Posłuszny W, Kopińska A, Subocz E, Masternak A, Guzicka-Kazimierczak R, Gil L, Machowicz R, Biliński J, Giebel S, Czerw T, Dwilewicz-Trojaczek J. Mądry K, et al. Among authors: bolkun l. Clin Lymphoma Myeloma Leuk. 2019 May;19(5):264-274.e4. doi: 10.1016/j.clml.2019.01.002. Epub 2019 Jan 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30898482

Cite

Share

8

Cite

Share

Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.

Robak T, Błoński J, Skotnicki AB, Piotrowska M, Wróbel T, Rybka J, Kłoczko J, Bołkun Ł, Budziszewska BK, Walczak U, Uss A, Fidecka M, Smolewski P. Robak T, et al. Among authors: bolkun l. Eur J Haematol. 2018 May;100(5):465-474. doi: 10.1111/ejh.13042. Epub 2018 Mar 22. Eur J Haematol. 2018. PMID: 29427355 Clinical Trial.

Cite

Share

9

Cite

Share

High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.

Romaniuk W, Bolkun L, Kalita J, Galar M, Bernatowicz M, Ostrowska H, Kloczko J. Romaniuk W, et al. Among authors: bolkun l. Ann Hematol. 2018 Oct;97(10):1879-1887. doi: 10.1007/s00277-018-3393-7. Epub 2018 Jun 26. Ann Hematol. 2018. PMID: 29946907 Free PMC article.

Cite

Share

10

Cite

Share

Very Small Embryonic-Like Stem Cells, Endothelial Progenitor Cells, and Different Monocyte Subsets Are Effectively Mobilized in Acute Lymphoblastic Leukemia Patients after G-CSF Treatment.

Eljaszewicz A, Bolkun L, Grubczak K, Rusak M, Wasiluk T, Dabrowska M, Radziwon P, Marlicz W, Kamiński K, Kloczko J, Moniuszko M. Eljaszewicz A, et al. Among authors: bolkun l. Stem Cells Int. 2018 Jun 21;2018:1943980. doi: 10.1155/2018/1943980. eCollection 2018. Stem Cells Int. 2018. PMID: 30034479 Free PMC article.

Cite

Share